Cargando…
Potential Therapeutic Options for COVID-19
The recently emerged coronavirus disease 2019 (COVID-19) has rapidly evolved into a pandemic with over 10 million infections and over 500 thousand deaths. There are currently no effective therapies or vaccines available to protect against this coronavirus infection. In this review, we discuss potent...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529694/ http://dx.doi.org/10.1097/IM9.0000000000000033 |
_version_ | 1784586521328746496 |
---|---|
author | Zheng, Xiaoqin Li, Lanjuan |
author_facet | Zheng, Xiaoqin Li, Lanjuan |
author_sort | Zheng, Xiaoqin |
collection | PubMed |
description | The recently emerged coronavirus disease 2019 (COVID-19) has rapidly evolved into a pandemic with over 10 million infections and over 500 thousand deaths. There are currently no effective therapies or vaccines available to protect against this coronavirus infection. In this review, we discuss potential therapeutic options for COVID-19 based on the available information from previous research on severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Substantial efforts are underway to discover new therapeutic agents for COVID-19, including the repurposing of existing agents and the development of novel agents that specifically target SARS-coronavirus 2 (SARS-CoV-2) or host factors. Through the screening of compound libraries, various classes of drugs, such as ribavirin, remdesivir, lopinavir/ritonavir, and hydroxychloroquine have been identified as potential therapeutic candidates against COVID-19. Novel antiviral drugs for SARS-coronavirus 2 are being developed to target viral enzymes or functional proteins, as well as host factors or cell signaling pathways. |
format | Online Article Text |
id | pubmed-8529694 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-85296942021-10-21 Potential Therapeutic Options for COVID-19 Zheng, Xiaoqin Li, Lanjuan Infectious Microbes & Diseases Review Article The recently emerged coronavirus disease 2019 (COVID-19) has rapidly evolved into a pandemic with over 10 million infections and over 500 thousand deaths. There are currently no effective therapies or vaccines available to protect against this coronavirus infection. In this review, we discuss potential therapeutic options for COVID-19 based on the available information from previous research on severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Substantial efforts are underway to discover new therapeutic agents for COVID-19, including the repurposing of existing agents and the development of novel agents that specifically target SARS-coronavirus 2 (SARS-CoV-2) or host factors. Through the screening of compound libraries, various classes of drugs, such as ribavirin, remdesivir, lopinavir/ritonavir, and hydroxychloroquine have been identified as potential therapeutic candidates against COVID-19. Novel antiviral drugs for SARS-coronavirus 2 are being developed to target viral enzymes or functional proteins, as well as host factors or cell signaling pathways. Lippincott Williams & Wilkins 2020-07-16 /pmc/articles/PMC8529694/ http://dx.doi.org/10.1097/IM9.0000000000000033 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-nc-sa/4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/) This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections. |
spellingShingle | Review Article Zheng, Xiaoqin Li, Lanjuan Potential Therapeutic Options for COVID-19 |
title | Potential Therapeutic Options for COVID-19 |
title_full | Potential Therapeutic Options for COVID-19 |
title_fullStr | Potential Therapeutic Options for COVID-19 |
title_full_unstemmed | Potential Therapeutic Options for COVID-19 |
title_short | Potential Therapeutic Options for COVID-19 |
title_sort | potential therapeutic options for covid-19 |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529694/ http://dx.doi.org/10.1097/IM9.0000000000000033 |
work_keys_str_mv | AT zhengxiaoqin potentialtherapeuticoptionsforcovid19 AT lilanjuan potentialtherapeuticoptionsforcovid19 |